TRDA
Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.13
−0.56%0
Insider buys (3m)
27
Insider sells (3m)
-$6.5M
Net value (3m)
+11.9%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | MPM BioVentures 2014, L.P. · 10 percent owner | Sale | 32,263 | $7.17 |
| Sep 3, 2026 | MPM BioVentures 2014, L.P. · 10 percent owner | Sale | 29,088 | $7.06 |
| Sep 3, 2026 | MPM BioVentures 2014, L.P. · 10 percent owner | Sale | 25,131 | $7.19 |
| Sep 3, 2026 | MPM BIOVENTURES 2018, L.P. · 10 percent owner | Sale | 29,088 | $7.06 |
| Sep 3, 2026 | Doshi Dipal · director, officer: CEO | F-InKind | 8,724 | $7.14 |
| Sep 3, 2026 | Sethuraman Natarajan · officer: President, Research & Develop. | F-InKind | 2,079 | $7.14 |
| Sep 3, 2026 | MPM BIOVENTURES 2018, L.P. · 10 percent owner | Sale | 32,263 | $7.17 |
| Sep 3, 2026 | MPM BIOVENTURES 2018, L.P. · 10 percent owner | Sale | 25,131 | $7.19 |
| Sep 3, 2026 | Dowden Nathan J · officer: President & COO | F-InKind | 2,528 | $7.14 |
| Sep 3, 2026 | WENTWORTH KORY JAMES · officer: Chief Financial Officer | F-InKind | 1,733 | $7.14 |
| Aug 31, 2026 | MPM BioVentures 2014, L.P. · 10 percent owner | Sale | 3,733 | $7.01 |
| Aug 31, 2026 | MPM BIOVENTURES 2018, L.P. · 10 percent owner | Sale | 44,259 | $6.99 |
| Aug 31, 2026 | MPM BIOVENTURES 2018, L.P. · 10 percent owner | Sale | 38,922 | $7.20 |
| Aug 31, 2026 | MPM BioVentures 2014, L.P. · 10 percent owner | Sale | 44,259 | $6.99 |
| Aug 31, 2026 | MPM BIOVENTURES 2018, L.P. · 10 percent owner | Sale | 3,733 | $7.01 |
| Aug 31, 2026 | MPM BioVentures 2014, L.P. · 10 percent owner | Sale | 38,922 | $7.20 |
| Aug 26, 2026 | MPM BIOVENTURES 2018, L.P. · 10 percent owner | Sale | 21,623 | $7.34 |
| Aug 26, 2026 | MPM BioVentures 2014, L.P. · 10 percent owner | Sale | 14,569 | $7.06 |
| Aug 26, 2026 | MPM BIOVENTURES 2018, L.P. · 10 percent owner | Sale | 14,569 | $7.06 |
| Aug 26, 2026 | MPM BIOVENTURES 2018, L.P. · 10 percent owner | Sale | 26,522 | $7.54 |
| Aug 26, 2026 | MPM BioVentures 2014, L.P. · 10 percent owner | Sale | 26,522 | $7.54 |
| Aug 26, 2026 | MPM BioVentures 2014, L.P. · 10 percent owner | Sale | 21,623 | $7.34 |
| Aug 10, 2026 | PARMAR KUSH · director | Sale | 52,317 | $6.85 |
| Aug 10, 2026 | PARMAR KUSH · director | Sale | 92,444 | $7.00 |
| Aug 10, 2026 | 5AM Ventures V, L.P. · 10 percent owner | Sale | 10,494 | $7.00 |
| Aug 10, 2026 | 5AM Ventures V, L.P. · 10 percent owner | Sale | 52,317 | $6.85 |
| Aug 10, 2026 | PARMAR KUSH · director | Sale | 10,494 | $7.00 |
| Aug 3, 2026 | 5AM Ventures V, L.P. · 10 percent owner | Sale | 114,756 | $6.93 |
| Aug 3, 2026 | 5AM Ventures V, L.P. · 10 percent owner | Sale | 1,718 | $6.85 |
| Aug 3, 2026 | PARMAR KUSH · director, 10 percent owner: | Sale | 1,718 | $6.85 |
Institutional positioning
13F filings over the trailing two quarters
New 47Increased 101Reduced 66Sold out 16
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BAKER BROS. ADVISORS LP | Unchanged | 5,072,730 | Aug 14, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 5,072,730 | May 15, 2026 |
| 5AM Venture Management, LLC | Unchanged | 4,056,379 | Aug 14, 2026 |
| 5AM VENTURE MANAGEMENT, LLC | Unchanged | 4,056,379 | May 15, 2026 |
| BlackRock, Inc. | Increased | 2,583,333 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 2,358,793 | May 13, 2026 |
| TCG CROSSOVER MANAGEMENT, LLC | Increased | 2,287,500 | May 15, 2026 |
| Merck & Co., Inc. | New Position | 1,739,768 | Aug 7, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 1,269,634 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,256,013 | May 15, 2026 |
| MPM BioImpact LLC | New Position | 1,253,053 | Aug 14, 2026 |
| TCG Crossover Management, LLC | Reduced | 1,060,230 | Aug 14, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 1,034,782 | May 15, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 954,419 | Aug 14, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 763,959 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 3, 2026